Navigation Links
Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized
Date:3/16/2011

IRVINE, Calif., March 16, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced the filing of its annual report on Form 10-K and certain revisions to its previously reported unaudited fourth quarter and full year 2010 financial results.

Upon finalization of the purchase price allocation related to Endologix's December 2010 acquisition of Nellix, Inc., the Company revised the amount of the purchase price allocated to in-process research and development (IPR&D) to $40.1 million and goodwill to $22.4 million.  Accordingly, the Company revised the associated deferred tax liability and the corresponding change in valuation allowance effect.  This resulted in an income tax benefit of $15.1 million compared to $11.3 million previously reported.  The revisions had no effect on cash flows or cash balances.

As a result, Endologix reported revised GAAP net earnings for the fourth quarter of 2010 of $11.7 million, or $0.22 per diluted share from the previously reported $8.0 million or $0.15 per diluted share; and GAAP net earnings for the full year 2010 of $10.7 million or $0.21 per fully diluted share from the previously reported $6.9 million or $0.14 per diluted share.

There were no other changes to Endologix's previously reported unaudited fourth quarter and full-year 2010 financial results, its previously reported adjusted (non-GAAP) results, or its previously reported financial guidance.Nellix Acquisition: Purchase Price Allocation($000's) Preliminary FinalizedIPR&D$

29,900$

40,100Deferred tax liability(11,302)(15,067)Other net assets114114Net assets acquired18,71225,147Fair value of consideration given$

47,589$

47,589Less: Net assets acquired18,71225,147Goodwill$

28,877$

22,442Effect on Reported Net IncomeQ4 2010($000's)Previ
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. Endologix Reports 30% Third Quarter 2010 Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
(Date:8/29/2014)... AMSTERDAM , August 29, 2014 ... invited to participate in the inaugural Tweetchat taking ... CPhI Worldwide , organised by UBM ... October 2014. #CPhIChat is a first of its ... media working across the supply chain, aimed to ...
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Gout ... Therapies such as Krystexxa, Uloric, Adenuric and ... http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html Gout Therapeutics ...
... that a new market research report is available in ... Testing Markets http://www.reportlinker.com/p089570/Cardiac-Marker-Diagnostic-Testing-Markets.html ... is to describe the specific market segment of the ... testing. This study examines clinical measurement devices and their ...
Cached Medicine Technology:Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:8/30/2014)... is a common problem millions of American cope with every day. ... nuisance, for some, it can have a crippling impact on social ... dramatic mood swings and depression. , Those struggling with acne ... In some cases, that can make the problem even worse. Instead ... a quest for clearer skin can now view acne treatment ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team of knowledgeable ... pleased to report having saved a client $67,100 on ... cases where Hastings and Hastings has tailored its fees ... portion of their settlement or recovery. The firm has ... for Arizona car accident victims is achievable through dedicated ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and ... her fever might get worse," said an inventor from ... of how she was doing, I developed this monitoring ... monitor a child's temperature. The unit instantly alerts parents ... prompt medical care can be given, which is designed ...
(Date:8/30/2014)... 30, 2014 "I had a handicapped friend ... crutches," said an inventor from Wetumpka, Ala. "In order to ... of the shore, I came up with a way for ... created a prototype for the patent-pending Deezers to allow crutches ... individual to use crutches, walkers, or canes at the beach. ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... Recommend Photochromic Lenses to Protect Eyes This Summer and ... Throughout the ... the dangers of extended sun exposure and its effects on the skin, ... survey conducted by,the New England Eye Institute and Transitions Optical found that ...
... to vote soon on legislation that would cut ... WASHINGTON, July 9 Seniors across Texas ... Advantage program in,legislation being considered in the U.S. ... from the Medicare Advantage program in Texas,alone and ...
... Additional Research Warranted on Impact of Medicare Modernization ... Shows Possibility of,Longer Wait Times for Patients in ... to a new study,released today in the July ... (JAMA), cancer patients experienced no major changes in ...
... 2006, a pneumococcal vaccine (Prevenar) was introduced in the ... experiences have been published in the journal Vaccine ... pneumococcal infections among young children. , Pneumococcus is ... young children, e.g. meningitis, blood poisoning and pneumonia. Most ...
... lumpectomy linked to depression, fear, study finds , , WEDNESDAY, ... who opt for breast-conserving cancer surgery say they now ... their quality of life, a new study says. , ... were twice as likely to fear their cancer returning ...
... Razadyne ER,from Tier 2 to Tier 3 When Generic Razadyne ... ... WALTHAM, Mass., July 9 Decision Resources, one of ... finds that the generic availability of,Shire/Janssen/Ortho McNeil,s Razadyne (galantamine) in ...
Cached Medicine News:Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Texas Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA) 2Health News:Vaccinated infants well-protected against severe pneumococcal infection in Norway 2Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
DH Autoflow Single Chamber Stackable Air-Jacketed CO2 Incubator...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
... from commonly used protein expression procedures using ... medium, contains two media, EXPANSION BROTH (EB) ... E. coli cells are grown in EB, ... is almost completely repressed. For high level ...
Medicine Products: